The real impact of flu for adults 65+:

  • 90% of all flu-related deaths are in people 65+3
  • Even though approximately 69% of all seniors get a yearly flu vaccination4
  • An estimated yearly average of 21,000 flu-related deaths (ranging from 2300 to 44,000) occurred in adults 65+3
  • Studies show that standard-dose flu vaccines prevent flu in only 30% to 40% of older adults vs more than 70% of young adults5

Comparing Standard-Dose Flu Vaccine Between Age Groups5

THE CONCLUSION: Older adults do not respond as well to standard-dose vaccination when compared with younger persons. This places adults 65+ at greater risk of influenza and its complications. Despite lower immune responses, both high-risk and healthy seniors derive substantial benefits from vaccination.5

back to top

the first flu vaccine designed specifically for patients 65+.1

the amount of each antigen of Fluzone vaccine gives seniors a higher level of flu-fighting antibodies for their declining immune system.1,5,6

Proven Superior Efficacy.1,2 Clinical Trial Results Published in the New England Journal of Medicine.

After vaccination with Fluzone High-Dose vaccine:

Primary endpoint of the study was the occurrence of laboratory-confirmed, protocol-defined, influenza-like illness caused by viral strains regardless of their antigenic similarity to
vaccine strains.1,2

A secondary endpoint of the study was the occurrence of culture-confirmed influenza caused by viral types/subtypes antigenically similar to those contained in the respective annual vaccine formulations in association with a modified Centers for Disease Control and Prevention–defined influenza-like illness.1,2

back to top

Reimbursement: Coverage Benefits that Help Your Patients–And You

  • Fluzone High-Dose vaccine is covered by Medicare Part B and by most Medicare Advantage plans with no copay
  • Plus, Fluzone High-Dose vaccine acquisition and administration fees are covered under Medicare Part B with no copay or deductible

COVERED BENEFIT SINCE 2010

  • An estimated 69% of Medicare beneficiaries are covered by Medicare Part B7
  • All Medicare Administrative Contractors are processing claims for Fluzone High-Dose vaccine8

Reimbursement codes

  • aCPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.
  • b ICD-10 = International Classification of Diseases, Tenth Revision.
back to top

Trusted by Physicians
since licensed in 2009.1,9

  • Nearly 70 million doses of Fluzone High-Dose vaccine sold since 20099
  • Approximately 60% of all seniors vaccinated against flu are estimated to have received
    Fluzone High-Dose vaccine9

Clinical efficacy study design:

31,803 adults ranging from 65 to 100 years of age
(with a median age of 70 years) made up the study population.1,c

Efficacy evaluated across multiple criteria:

Influenza virus types and subtypes

Influenza A (H1N1), A (H3N2), and B strains2

SimilaritY of strains

Vaccine strains that were well matched or not well matched to the circulating strains1,2

ACROSS 2 FLU SEASONS

2011-2012 and 2012-20131

c Per-protocol analysis set for efficacy assessments.1

DEMONSTRATED SAFETY WITH FLUZONE HIGH-DOSE VACCINE FOR ADULTS 65+ IN A PHASE III TRIAL1

Solicited injection-site reactions and systemic adverse events were more frequent after vaccination with Fluzone High-Dose vaccine compared with Fluzone vaccine in adults 65+.10

d N = Number of subjects with available data for events listed.

back to top

PLEASE NOTE

By clicking on this link, you will be leaving this Sanofi Pasteur website and going to another, entirely independent website. Sanofi Pasteur provides this link as a service to its website visitors; however, it takes no responsibility for the information presented on any website but its own.

This link has opened in a new window. To return to your original site, please close this new window.

Click here to go to the page you requested. Click here to close this window and return to the site.

PLEASE NOTE

By clicking on this link, you will be leaving this Sanofi Pasteur website and going to another Sanofi Pasteur website.

This link has opened in a new window. To return to your original site, please close this new window.

Click here to go to the page you requested. Click here to close this window and return to the site.